article thumbnail

Regeneron confirms FDA won’t approve myeloma drug over manufacturing issues

Bio Pharma Dive

Company executives had previously warned investors that a delay was likely due to issues at a facility run by third-party manufacturer.

article thumbnail

Biotechnology Equipment Manufacturers, Companies and Suppliers for the Pharmaceutical Industry

Pharmaceutical Technology

Discover the leading Biotechnology Equipment Manufacturers, Companies and Suppliers. Download the free Buyer's Guide today for full details.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gene therapy biotech Jaguar spins out manufacturing company

Bio Pharma Dive

Called Advanced Medicine Partners, the new company will offer specialized cell and gene therapy manufacturing services to biotech and pharma clients.

article thumbnail

German CDMO outlays $980m on GLP-1 manufacturing expansion

Pharmaceutical Technology

As the EU anticipates GLP-1RA shortages throughout 2024, Corden Pharma has pledged $980m to increase manufacturing capacity.

article thumbnail

Making the Case for Case Management for Cell and Gene Therapies

A dedicated Case Manager provides end-to-end supply chain management and 24/7 oversight and support to help ensure the seamless manufacturing and distribution of each therapy dose to every patient.

article thumbnail

Rocket gene therapy rejected by FDA over manufacturing

Bio Pharma Dive

The complete response letter follows other recent manufacturing-related rejections, including one for a cell therapy from Abeona Therapeutics.

article thumbnail

Eli Lilly to invest $1.8bn in manufacturing capacity in Ireland

Pharmaceutical Technology

Lilly has announced a significant expansion of its manufacturing presence in Ireland, with a $1bn investment earmarked for its Limerick site.

article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial.